Market revenue in 2023 | USD 245.6 million |
Market revenue in 2030 | USD 273.4 million |
Growth rate | 1.5% (CAGR from 2023 to 2030) |
Largest segment | Antacids |
Fastest growing segment | H2 Receptor Blockers |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Antacids, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs), Pro-kinetic agents |
Key market players worldwide | AstraZeneca PLC, Eisai Co Ltd, GSK PLC, Takeda Pharmaceutical Co Ltd, Ironwood Pharmaceuticals Inc Class A, Johnson & Johnson, Phathom Pharmaceuticals Inc Ordinary shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gastroesophageal reflux disease therapeutics market will help companies and investors design strategic landscapes.
Antacids was the largest segment with a revenue share of 56.68% in 2023. Horizon Databook has segmented the Canada gastroesophageal reflux disease therapeutics market based on antacids, h2 receptor blockers, proton pump inhibitors (ppis), pro-kinetic agents covering the revenue growth of each sub-segment from 2018 to 2030.
According to Canadian Society of Intestinal Research, GERD is the most prevalent acid associated disorder in Canada. Around 13% of the Canadian population suffers from GERD on a weekly basis. Approximately 24% of the population experiences acid reflux on a daily basis.
As per a study of 6,000 patients, the quality of life has declined in Canada. Around 75% of GERD patients in the country prefer self-medication. Increase in awareness pertaining to GERD is likely to have a positive impact on the market growth.
The Canadian Association of Gastroenterology provides education and research grants and funds for gastrointestinal health and disease research. The organization has also created evidence-based practice guidelines for the diagnosis and treatment of GERD.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada gastroesophageal reflux disease therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Canada gastroesophageal reflux disease therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account